Taysha Gene Therapies, Inc. (TSHA)

2,3400 -0,1900 (-7,51%) Al cierre: 04:00PM EDT

Taysha Gene Therapies, Inc.

3000 Pegasus Park Drive
Suite 1430
Dallas, TX 75247
United States
214 612 0000
https://www.tayshagtx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 52

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Sean P. Nolan	CEO & Chairman	925,33k	N/A	1968
Dr. Sukumar Nagendran M.D.	President, Head of Research & Development and Director	820,59k	N/A	1967
Mr. Kamran Alam CPA, M.B.A.	CFO & Corporate Secretary	573,36k	N/A	1978
Hayleigh Collins	Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Tracy M. Porter SPHR	Chief People Officer	N/A	N/A	N/A
Mr. Frederick Porter Ph.D.	Chief of Staff & Technical Operations Officer	N/A	N/A	N/A
Ms. Emily McGinnis M.P.H.	Chief Patient Advocacy & External Affairs Officer	N/A	N/A	N/A
Mr. Sean McAuliffe	Chief Business Officer	N/A	N/A	N/A
Dr. Steven Gray Ph.D.	Chief Scientific Advisor of UT Southwestern Gene Therapy Program	N/A	N/A	N/A
Berge Minassian M.D.	Chief Medical Advisor of UT Southwestern Gene Therapy Program	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Gobierno corporativo

El ISS Governance QualityScore de Taysha Gene Therapies, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.